In July 2023, Biogen said it would cut another 1,000 jobs on top of the nearly 1,000 positions globally it eliminated in 2022. CEO Christopher Viehbacher said in Monday’s announcement that ...

Biogen has relied on cost cuts, multiple acquisitions and a narrowed focus on new launches to boost profit since CEO Christopher Viehbacher took the top role in 2022. McDonnell, who has been the ...

although he will remain at the helm of Biogen until a new CEO is found to help oversee a revitalisation of the company. First-quarter revenues fell 6% to just over $2.5 billion as top earners ...

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

(Reuters) -Biogen raised its annual profit forecast and exceeded expectations for third-quarter profit on Wednesday, as new treatments and ... potential products as CEO Christopher Viehbacher ...

We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at ...

Biogen’s CEO also acknowledged the difficulties in pinpointing ... Behind the scenes, there was a 40% uptick in the number of new prescribers writing prescriptions for Leqembi in the third ...

“Recent pipeline setbacks require us to further focus our business priorities,” Sage CEO ... Sage and Biogen Inc. (Nasdaq: BIIB) scored a win when the FDA approved zuranolone, a new medicine ...

Oct 30 (Reuters) - Biogen (BIIB.O), opens new tab raised its annual profit forecast ... as part of a series of cost-saving measures, as CEO Christopher Viehbacher takes the lead to bring the ...

(Reuters) - Biogen raised its annual profit forecast on Wednesday, as new treatments and cost-cutting ... of a series of cost-saving measures, as CEO Christopher Viehbacher takes the lead to ...